GLP-1 weight loss claims on TikTok: separating signal from noise

What did @sierra.robichaud actually say?

Sierra tracked her weight weekly during her first month on compounded tirzepatide, starting at 197.4 pounds on October 27th. She lost 9.4 pounds over four weeks, with most of the loss coming in weeks one and three. She skipped her injection during Thanksgiving week and gained 0.7 pounds. She then compared this to her first month on Wegovy, where she lost about 10 pounds at a steadier pace of roughly four pounds the first week and two pounds every week after.

The core comparison she's drawing: tirzepatide gave her "a lot more drastic" swings week to week, but the total one-month result was nearly identical to Wegovy. That's an honest, data-forward summary. She also flagged that her big first-week drop was likely water weight due to bloating, which shows real self-awareness about how these numbers work.

Does the science back this up?

Broadly, yes. The pattern she's describing is consistent with what clinical trials have shown for both drugs, with some important caveats.

The SURMOUNT-1 trial (Jastreboff et al., 2022, New England Journal of Medicine) showed tirzepatide produced up to 20.9% body weight reduction over 72 weeks at the highest dose. The STEP 1 trial for semaglutide (Wegovy's active ingredient) showed about 14.9% reduction over 68 weeks (Wilding et al., 2021, NEJM). Tirzepatide's dual GIP and GLP-1 receptor agonism is thought to explain its stronger average efficacy over time, though her first-month numbers being nearly equal is also realistic. Early weeks on GLP-1 drugs are dominated by water weight and reduced food intake, not fat loss, which she correctly intuited.

The variability she saw with tirzepatide week to week, compared to steadier loss on Wegovy, is plausible but individual. There is no head-to-head trial data establishing that tirzepatide produces more erratic weekly fluctuations than semaglutide in general populations.

What did they get wrong (or right)?

She gets credit for being precise. Actual numbers, actual dates, and an honest week where she gained weight because she forgot her shot. That kind of transparency is rare in this content category.

The biggest issue is terminology. She calls the drug "tricepotide" throughout, which is not a real drug name. The medication she's describing is tirzepatide, sold under brand names Mounjaro and Zepbound. Mispronouncing or misspelling it as "tricepotide" is a problem in a health content context because it makes the drug harder to search, verify, or discuss with a provider. It is not a minor slip when 50,000 people are watching.

She also calls the brand Wegovy "wagobi," which is another mispronunciation. These are not trivial. Someone who hears this and asks their doctor about "tricepotide" may create confusion.

One more thing worth flagging: she is using a compounded version of tirzepatide. Compounded tirzepatide is not FDA-approved and is not the same product as brand-name Zepbound or Mounjaro. The purity, concentration, and inactive ingredients can differ. She does not mention this distinction, which matters.

What should you actually know?

First-month weight loss on GLP-1 and dual GIP/GLP-1 agonists is heavily influenced by water weight, starting body composition, diet, and whether someone actually took their shots consistently. Sierra's experience is real, but it is one data point.

The skip-a-week scenario she described is worth paying attention to. Missing a dose of tirzepatide and gaining 0.7 pounds in the context of a holiday week is a mild outcome, but inconsistent dosing affects drug levels and appetite suppression in ways that compound over time. The prescribing guidance for tirzepatide is clear that missed doses should be taken within four days or skipped entirely if closer to the next scheduled dose.

If you are comparing your own results to hers, consider that she started at 197.4 pounds. Absolute pound loss at higher starting weights will typically be larger in early weeks. Percentage body weight loss is a more meaningful comparison across different starting points.

Finally, compounded tirzepatide exists in a complicated regulatory space. The FDA has stated that tirzepatide shortage designations have changed, which affects whether compounding pharmacies can legally produce it. Anyone using compounded tirzepatide should confirm their pharmacy's compliance status and discuss the distinction between compounded and brand-name products with their prescriber.